It makes sense and I agree with you and BL about the current status of leronlimab partnership. Hopefully the SA article is correct about NSTG cash position being for the PCa test.

While I hope CYDY doesn’t try to go alone, if something isn’t inked by late fall or when BLA is filed, I would think they would have to be leaning that way or at least making plans for such. I don’t think this will be the case and hopefully cancer results will bring in multiple bids with more favorable terms for CYDY. Delaying a little while is smart for CYDY at this point even though it is frustrating for us watching from the sidelines.